Emergent BioSolutions (EBS) Total Current Liabilities (2010 - 2026)

Emergent BioSolutions' Total Current Liabilities history runs 17 years deep, the most recent figure standing at $148.7 million for Q1 2026.

• On a quarterly basis, Total Current Liabilities rose 32.89% year-over-year to $148.7 million in Q1 2026; TTM through Mar 2026 was $148.7 million, a 32.89% increase from a year earlier, with the FY2025 full-year figure at $132.2 million, down 18.6% from the prior year.
• Total Current Liabilities grew to $148.7 million in Q1 2026 per EBS's latest filing, from $132.2 million in the prior quarter.
• Across five years, Total Current Liabilities topped out at $1.2 billion in Q4 2022 and bottomed at $111.9 million in Q1 2025.
• The 5-year median for Total Current Liabilities is $264.4 million (2022), against an average of $443.6 million.
• Across the five-year window, Total Current Liabilities surged 387.84% in 2023 and sank 82.24% in 2025, its largest moves.
• Year by year, Total Current Liabilities stood at $1.2 billion in 2022, then tumbled by 47.0% to $651.3 million in 2023, then plunged by 75.07% to $162.4 million in 2024, then fell by 18.6% to $132.2 million in 2025, then grew by 12.48% to $148.7 million in 2026.
• Per Business Quant, the three latest EBS Total Current Liabilities figures stand at $148.7 million (Q1 2026), $132.2 million (Q4 2025), and $136.5 million (Q3 2025).